Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998048818) ACTIVATED PROTEIN C FORMULATIONS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/048818 International Application No.: PCT/US1998/008386
Publication Date: 05.11.1998 International Filing Date: 24.04.1998
Chapter 2 Demand Filed: 23.11.1998
IPC:
A61K 38/48 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43
Enzymes; Proenzymes; Derivatives thereof
46
Hydrolases (3)
48
acting on peptide bonds (3.4)
Applicants:
ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, IN 46285, US (AL, AM, AU, AZ, BA, BB, BF, BG, BJ, BR, BY, CA, CF, CG, CI, CM, CN, CU, CZ, EE, GA, GE, GH, GM, GN, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, ML, MN, MR, MW, MX, NE, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW)
CARLSON, Andrew, David [US/US]; US (UsOnly)
SHELIGA, Theodore, Arsay [US/US]; US (UsOnly)
Inventors:
CARLSON, Andrew, David; US
SHELIGA, Theodore, Arsay; US
Agent:
CALTRIDER, Steven, P. ; Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285, US
Priority Data:
60/045,25528.04.1997US
Title (EN) ACTIVATED PROTEIN C FORMULATIONS
(FR) FORMULATIONS DE PROTEINE ACTIVEE
Abstract:
(EN) The present invention relates to pharmaceutical formulations of activated protein C which also comprises sucrose, sodium chloride and sodium citrate buffer at a pH between about 5.5 and about 6.5. The activated protein C formulations of the present invention are more stable than other formulations of activated protein C and demonstrate fewer degradation products over time.
(FR) Ces formulations pharmaceutiques à base de protéine C activée comportent également du sucrose, du chlorure de sodium et un tampon citrate de sodium dont le pH se situe entre environ 5,5 et 6,5. Les formulations à base de protéine C activée de la présente invention sont plus stables que d'autres formulations de protéine C activée et donnent à terme moins de produits de dégradation.
Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CZPV1999-3810NO19995198TR1999/02529MXPA/a/1999/009595KR1020010020325SG68927
VN4286IL132325JP2001524111 CN1254284CA2288143EA199900979
NZ337828AU1998072589